May 29, 2020

Myovant Sciences Announces Additional Positive Efficacy and Cardiovascular Safety Data from Phase 3 HERO Study of Once-Daily, Oral Relugolix in Advanced Prostate Cancer and Publication in the New England Journal of Medicine

May 18, 2020

Myovant Sciences Provides Recent Corporate Updates and Reports Financial Results for Fourth Fiscal Quarter and Full Fiscal Year Ended March 31, 2020

May 14, 2020

Myovant Sciences to Present New Data on Relugolix in Prostate Cancer at American Society of Clinical Oncology (ASCO) 2020 Annual Meeting

April 27, 2020

Myovant Sciences Announces Publication of Abstracts Detailing Additional Efficacy and Safety Findings from Phase 3 LIBERTY Studies in Uterine Fibroids in Obstetrics & Gynecology

April 22, 2020

Myovant Sciences Announces Positive Results from Phase 3 SPIRIT 2 Study Evaluating Once-Daily Relugolix Combination Therapy in Women with Endometriosis and from Ovulation Inhibition Study

April 21, 2020

Myovant Sciences to Host Webcast and Conference Call at 8:30 a.m. Eastern Time Wednesday, April 22 to Discuss Results from Phase 3 SPIRIT 2 Study Evaluating Once-Daily Relugolix Combination Therapy in Women with Endometriosis and from Ovulation Inhibition

April 21, 2020

Myovant Sciences Submits New Drug Application (NDA) to the FDA for Once-Daily, Oral Relugolix for the Treatment of Men with Advanced Prostate Cancer

April 14, 2020

Myovant Sciences and HealthyWomen Launch Storytelling Initiative to Elevate Conversations About Menstrual Health

March 31, 2020

Myovant Sciences and Gedeon Richter Enter into Exclusive License Agreement to Commercialize Relugolix Combination Tablet for Uterine Fibroids and Endometriosis in Certain Territories Outside the U.S.

March 10, 2020

Myovant Sciences Announces Cancellation of Presentation and Webcast at the Barclays Global Healthcare Conference 2020